EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Anca Streinu-Cercel iD, Antonella Castagna iD, Shan-Chwen Chang iD, Yao-Shen Chen, Yiannis Koullias iD, Afsaneh Mozaffarian, Robert H Hyland iD, Rita Humeniuk iD, Luzelena Caro iD, Santosh Davies, Lauren Rodriguez iD, Charlotte Hedskog iD und 12 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf406 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Anca Streinu-Cercel und 23 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obeldesivir is an oral nucleoside analog prodrug inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Methods

Nonhospitalized adults with risk factors for developing severe coronavirus disease 2019 (COVID-19) were enrolled ≤5 days from COVID-19 symptom onset and randomized 1:1 to receive obeldesivir 350 mg or placebo twice daily for 5 days. The primary end point was COVID-19–related hospitalization or all-cause death by day 29. Other end points included time to symptom alleviation by day 15, change in SARS-CoV-2 viral RNA copy number and infectious viral titer, and incidence of adverse events and laboratory abnormalities.

Results

Four hundred and sixty five participants were randomized and received ≥1 dose of study drug. Baseline characteristics were generally balanced between groups. Overall, 58% had received ≥1 COVID-19 vaccination, and 92% were seropositive for SARS-CoV-2 antibodies. COVID-19–related hospitalization or all-cause death by day 29 was reported in 0 of 211 (0%) participants with obeldesivir and 1 of 207 (0.5%) participants with placebo (log-rank P = .32). Time to COVID-19 symptom alleviation was numerically shorter with obeldesivir versus placebo. Obeldesivir reduced viral RNA copy number at day 5 and infectious titer at days 3 and 5 versus placebo. The safety profile was generally comparable across arms.

Conclusions

Although underpowered in the context of a changing COVID-19 landscape, obeldesivir in nonhospitalized adults with targeted risk factors did not improve COVID-19–related hospitalization or all-cause death. Obeldesivir reduced viral RNA copy number and infectious titer, demonstrating its ability to inhibit SARS-CoV-2 replication, and resulted in numerically faster symptom alleviation. Clinical Trials Registration NCT05603143; EudraCT 2022-002741-18.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19 Drug TreatmentHumansMaleFemaleMiddle AgedDouble-Blind MethodSARS-CoV-2AdultAgedCOVID-19Viral LoadRNA, ViralTreatment OutcomeHospitalization

Stichwörter der Autor:innen

COVID-19SARS-CoV-2antiviralobeldesivir

Substanzen

Antiviral AgentsRNA, Viral

Autor:innen und Institutionen

  • Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Inpatient Adult 5 Infectious Diseases and HIV Department, National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania.
  • Infectious Diseases Clinic, Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Administration, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
  • Gilead Sciences, Inc, Foster City, California, USA.

ORCID-Profile: Anca Streinu-Cercel, Antonella Castagna, Shan-Chwen Chang, Yiannis Koullias, Robert H Hyland, Rita Humeniuk, Luzelena Caro, Lauren Rodriguez, Charlotte Hedskog, Jesus Abraham Simon-Campos, Fabio Eudes Leal, Leon F Fouche, Juan Maria González Del Castillo

Förderung

  • Gilead Sciences, Inc

Zitieren

APA

Streinu-Cercel, A., Castagna, A., Chang, S. C., Chen, Y. S., Koullias, Y., Mozaffarian, A., Hyland, R. H., Humeniuk, R., Caro, L., Davies, S., Rodriguez, L., Hedskog, C., Chen, S., Etchevers, K., Behenna-Renton, N., Llewellyn, J., Osinusi, A., Duff, F., Barrat Hernández, A., …, & González Del Castillo, J. M. (2026). Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf406

Vancouver

Streinu-Cercel A, Castagna A, Chang SC, Chen YS, Koullias Y, Mozaffarian A, et al. Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf406

BibTeX
@article{StreinuCercel2026,
  author = {Streinu-Cercel, Anca and Castagna, Antonella and Chang, Shan-Chwen and Chen, Yao-Shen and Koullias, Yiannis and Mozaffarian, Afsaneh and Hyland, Robert H and Humeniuk, Rita and Caro, Luzelena and Davies, Santosh and Rodriguez, Lauren and Hedskog, Charlotte and Chen, Shuguang and Etchevers, Kim and Behenna-Renton, Nicole and Llewellyn, Joe and Osinusi, Anu and Duff, Frank and Barrat Hernández, Alejandro and McNally, Damien and Simon-Campos, Jesus Abraham and Leal, Fabio Eudes and Fouche, Leon F and González Del Castillo, Juan Maria},
  title = {Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf406}
}
Kostenlos starten →